Drugs / sofosbubir/velpatasvir/voxilaprevir
sofosbubir/velpatasvir/voxilaprevir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03888729 | Aug 2019 → Mar 2020 | chronic hepatitis C virus infection | Partners in Health | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sofosbubir/velpatasvir/voxilaprevir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03888729 ↗ |
| Known as | SOF/VEL/VOX | “Sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) will be administered once daily for 12 weeks to eligible HCV treatment-experienced participants” NCT03888729 ↗ |
| Known as | sofosbuvir-velpatasvir-voxilaprevir | “Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment...” PMID 35248212 ↗ Mar 2022 |
| Route | Oral | “Participants were treated once daily with an oral fixed-dose combination tablet containing sofosbuvir (400 mg), velpatasvir (100 mg), and voxilaprevir (100 mg) for 12 weeks.” PMID 35248212 ↗ Mar 2022 |